Drug facts

Retatrutide vs tirzepatide

Quick answer

Tirzepatide is an approved medicine that activates two receptors. Retatrutide activates three and is still in clinical trials — there is no approved retatrutide product in the United States or anywhere else, for any condition. The published trials are real and the weight figures in them are large, but they were measured on a drug you cannot yet be prescribed.

The difference that matters most

It is not the third receptor. It is that one of these has been through FDA review and the other has not been through it anywhere.

Tirzepatide is sold as Mounjaro and Zepbound, with a label that states what it is approved for, what it must warn about, and how it is made. Retatrutide has none of that yet. Its manufacturer is still running the trials that would produce it. That is not a criticism of the molecule — it is a description of how much is currently known about giving it to people outside a trial, which is: much less.

The rest of this site is about compounded tirzepatide, where the molecule itself is approved and the preparation is not reviewed. Retatrutide is a step further out than that, and the distinction is worth holding onto.

Two receptors against three3

Tirzepatide’s own label describes it as a GIP receptor and GLP-1 receptor agonist — two targets. Retatrutide is described in its published trials as an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. The glucagon arm is the new one, and it is the reason the drug is interesting: glucagon receptor activity is associated with energy expenditure rather than appetite alone.

A third target is not automatically a better drug. It is a different drug, with its own side-effect profile to establish — and establishing it is what the trials below are for.

What the retatrutide trials measured1

The phase 2 obesity trial enrolled 338 adults and reported, at 48 weeks, a least-squares mean change in body weight of −8.7% at 1 mg, −17.1% in the combined 4 mg group, −22.8% in the combined 8 mg group and −24.2% at 12 mg, against −2.1% on placebo. At 24 weeks the same groups were at −7.2%, −12.9%, −17.3% and −17.5%, against −1.6% on placebo.

The trial also reported how many people crossed each threshold at 48 weeks: on 12 mg, 100% lost at least 5%, 93% at least 10% and 83% at least 15%, against 27%, 9% and 2% on placebo. The most common adverse events were gastrointestinal, dose-related and mostly mild to moderate, and dose-dependent increases in heart rate peaked at 24 weeks before declining.

2A phase 3 trial in type 2 diabetes has since reported. It randomized 537 adults whose diabetes was not controlled by diet and exercise alone, and at 40 weeks reported mean weight change of −11.5% at 4 mg, −13.9% at 9 mg and −15.3% at 12 mg against −2.6% on placebo, alongside HbA1c reductions of 1.69, 1.86 and 1.94 percentage points against 0.81 on placebo. Two deaths occurred during that study, both in the 4 mg group, and the investigators reported both as unrelated to the study drug.

Why you cannot compare the two numbers

It is tempting to set retatrutide’s −24.2% beside a tirzepatide figure and call one bigger. That comparison is not available from these papers, and here is why.

The two drugs have not been tested against each other. Every figure above comes from a trial comparing retatrutide with placebo, in its own population, over its own duration, with its own entry criteria. The phase 2 obesity trial ran 48 weeks in adults with obesity; the phase 3 trial ran 40 weeks in adults with type 2 diabetes, who lose less weight on these drugs than people without it. Reading across trials is how a drug acquires a reputation it has not earned — the same error this site spends its time on in the tirzepatide against semaglutide comparison, where a head-to-head trial does exist and is still widely misquoted. That trial is a direct comparison of two other drugs and does not answer the retatrutide question.

What can be said is narrower and more useful: retatrutide has produced large weight reductions against placebo in two randomized trials, one of them phase 3, and nobody has yet published a trial putting it against tirzepatide.

What is being sold online

Retatrutide is sold today by sellers who describe it as a research chemical, and by some who do not describe it that way at all. There is no approved product for them to be compounding from, no label to dispense against, and no established dose outside a trial protocol.

This site does not index those sellers and does not price them. It indexes compounded tirzepatide, where an approved product exists and a reader can be told exactly how their vial differs from it. A molecule whose own trials are still reporting has no such reference point.

4FDA names retatrutide directly. It has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that were falsely labeled “for research purposes” or “not for human consumption,” and it urges consumers not to buy them. What those vials are, and what FDA found on the sites selling them, is on tirzepatide sold as a “research” powder.

Can you switch from tirzepatide to retatrutide?4

Not to an approved medicine, because there isn’t one. No prescriber can move you from Zepbound, Mounjaro or a compounded tirzepatide vial onto an FDA-approved retatrutide product. What is sold online as retatrutide is the “research use only” product FDA has warned about by name.

There is also no evidence on how to make the switch. No published trial has tested moving people from tirzepatide to retatrutide, so there is no studied starting dose, waiting period or escalation for it. The retatrutide doses quoted above are trial protocol doses in people who were starting the drug, not a map for changing over. If you are thinking about it because tirzepatide has stopped working or is hard to tolerate, that is a conversation for your prescriber, who can change an approved treatment on the record. Why “research” vials are a different market →

Can you take tirzepatide and retatrutide together?5

The tirzepatide label advises against it. Its limitations of use say that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. Retatrutide is a GLP-1 receptor agonist, on top of its GIP and glucagon activity, so it falls inside that warning. The two drugs overlap on two of the same receptors, and no published trial has given them together.

6Combined products are being sold anyway. In August 2026 FDA sent a warning letter to a seller of tirzepatide vials whose site also offered a tirzepatide-and-retatrutide mixed kit.

Questions

Is retatrutide better than tirzepatide?
That is not yet known. The two drugs have never been tested against each other in a published trial. Retatrutide's published results come from placebo-controlled trials in their own populations, and retatrutide has no approved product anywhere, while tirzepatide is approved as Zepbound and Mounjaro.
Can you switch from tirzepatide to retatrutide?
Not to an approved product, because none exists. No published trial has tested switching from tirzepatide to retatrutide. Retatrutide sold online is sold as a research chemical, and FDA has warned companies that illegally sold retatrutide falsely labeled for research purposes.
Can you take tirzepatide and retatrutide together?
The tirzepatide label advises against it. It states that using tirzepatide with any GLP-1 receptor agonist is not recommended, and retatrutide is a GLP-1 receptor agonist as well as a GIP and glucagon receptor agonist. No published trial has tested the two together.
Is retatrutide FDA-approved?
No. Retatrutide is still in clinical trials and has no approved product in the United States or anywhere else.

Nothing here is a dosing instruction or a recommendation. Whether any of these medicines is appropriate for you is a question for a prescriber who knows your history, and the doses above are quoted from trial protocols to describe what was measured.

Sources

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. NCT04881760. PubMed
  2. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. PMID: 42250575. NCT06354660. PubMed
  3. FDA prescribing information for ZEPBOUND (tirzepatide), sections 1 and 12.1, revision 4/2026 DailyMed
  4. FDA, 'FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss', content current as of 09/01/2026 FDA
  5. FDA prescribing information for ZEPBOUND (tirzepatide), section 1, Limitations of Use, revision 8/2026 DailyMed
  6. FDA warning letter to Royal Peptides LLC, MARCS-CMS 734884, 24 August 2026